Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging (DOSI)

The prospective multi-center ACRIN 6691 trial was designed to evaluate whether changes from baseline to mid-therapy in a Diffuse Optical Spectroscopic Imaging (DOSI)-derived imaging endpoint, the Tissue Optical Index (TOI), predict pathologic complete response (pCR) in women undergoing breast cancer...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Tromberg, Bruce J., Zhang, Zheng, Leproux, Anaïs, O’Sullivan, Thomas D., Cerussi, Albert E., Carpenter, Philip, Mehta, Rita S., Roblyer, Darren, Yang, Wei, Paulsen, Keith D., Pogue, Brian W., Jiang, Shudong, Kaufman, Peter, Yodh AG, Arjun G., Chung, So Hyun, Schnall, Mitchell, Snyder, Bradley S., Hylton, Nola, Boas, David A., Carp, Stefan A., Isakoff, Steven J., Mankoff, David
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5148152/
https://ncbi.nlm.nih.gov/pubmed/27527559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0346
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares